LITERATURE REVIEW: EFFECT OF EXERCISE ON SERUM FGF23

Exercise is an activity that has many health benefits, including bone, heart, and muscle health. One of the proteins found to be increased after exercise was FGF23. FGF23 is one of the bone mineral regulators which previously served as an indicator for chronic kidney disease severity and cardiovascular morbidity. However, some studies have found no increase in FGF23 after exercise. The purpose of this study is to elucidate the effect of exercise on serum FGF23. This study is a literature review with a qualitative approach comparing previous studies related to exercise and FGF23. From 13 selected kinds of literature, serum FGF23 elevation was found on exercise for one day to three weeks and did not change after six weeks to 12 months of exercise. The conclusions of the study are serum FGF23 was found to be increased after one day to three weeks of exercise and serum FGF23 in human studies found to be increased after long-duration maximal-intensity exercise.

Download Full-text

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review

Advances in Therapy ◽

10.1007/s12325-020-01607-4 ◽

2021 ◽

Vol 38 (2) ◽

pp. 994-1010

Author(s):

Oliver Darlington ◽

Carissa Dickerson ◽

Marc Evans ◽

Phil McEwan ◽

Elisabeth Sörstadius ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Literature Review ◽

Systematic Literature Review ◽

Resource Use ◽

Healthcare Resource ◽

Cardiovascular Morbidity ◽

Healthcare Resource Use

Download Full-text

Mineral metabolism, cortical volumetric bone mineral density and fracture risk in childhood chronic kidney disease

Bone Abstracts ◽

10.1530/boneabs.2.oc29 ◽

2013 ◽

Author(s):

Denburg Michelle ◽

Tsampalieros Anne ◽

de Boer Ian ◽

Shults Justine ◽

Kalkwarf Heidi ◽

...

Keyword(s):

Bone Mineral Density ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Fracture Risk ◽

Bone Mineral ◽

Mineral Metabolism ◽

Volumetric Bone Mineral Density ◽

Mineral Density

Download Full-text

Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review

Arthritis Research & Therapy ◽

10.1186/s13075-021-02416-y ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Huai Leng Pisaniello ◽

Mark C. Fisher ◽

Hamish Farquhar ◽

Ana Beatriz Vargas-Santos ◽

Catherine L. Hill ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Renal Function ◽

Kidney Disease ◽

Literature Review ◽

Interleukin 1 ◽

Treatment Options ◽

Cochrane Library ◽

Efficacy And Safety ◽

Clinical Trial Results ◽

Gout Flare

AbstractGout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3–5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m2), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and/or safety analysis stratified by renal function were reviewed—colchicine (n = 20), anakinra (n = 7), canakinumab (n = 1), NSAIDs (n = 3), and glucocorticoids (n = 2). A total of 58 studies reported these primary outcomes without renal function stratification—colchicine (n = 29), anakinra (n = 10), canakinumab (n = 6), rilonacept (n = 2), NSAIDs (n = 1), and glucocorticoids (n = 10). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of < 30 mL/min/1.73 m2). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition.

Download Full-text